Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

DEER PARK, Ill. and WARREN, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, and Aquestive Therapeutics, Inc. (“Aquestive”) (Nasdaq: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that they have entered into an exclusive license agreement and a supply agreement covering the United States and its territories for LIBERVANT® (diazepam) buccal film, an Orphan Drug-designated, differentiated treatment for seizure clusters in patients with epilepsy. Eton anticipates commercial availability of LIBERVANT in April 2027, subject to final U.S. Food and Drug Administration (FDA) approval.

GlobeNewsWire • Oct 14, 2026

ETON Stock Surges 108% in Six Months: Here's What You Need to Know

Eton's sales surge, raised 2026 outlook and expanding rare-disease portfolio are boosting confidence in its growth.

Zacks Investment Research • Oct 7, 2026

Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules

DEER PARK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the Company has launched IMPAVIDO® (miltefosine) capsules.

GlobeNewsWire • Sep 28, 2026

Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference being held September 8-10, 2026 in Boston, MA.

GlobeNewsWire • Aug 27, 2026

Three Biotech Stocks Stick Out With Their Stellar Charts

These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.

Investors Business Daily • Aug 21, 2026

Why Eton Pharmaceuticals Is Top of the Class Today

Eton Pharmaceuticals beat on both top and bottom lines last night. Management is licensing a new drug, and raising guidance through the end of 2026.

The Motley Fool • Aug 14, 2026

Why Top 3% Biotech Stock, Eton, Just Catapulted To A Record High

Eton stock catapulted to a record high Friday after the biotech company smashed second-quarter sales forecasts and hiked its guidance.

Investors Business Daily • Aug 14, 2026

Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript

Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 14, 2026

Eton Pharmaceuticals: No Reason Pharma Can't Deliver More Great Earnings Like These

Eton Pharmaceuticals, Inc. delivered record Q2 2026 results, with product sales up 99% and full-year revenue guidance raised to over $145 million. ETON targets over $500 million in peak annual sales by leveraging organic growth, pipeline development, and strategic acquisitions in rare disease markets. Management expects adjusted EBITDA margins to exceed 35% in 2026, aiming for 50% by 2028, with gross margins rising from 70% to over 75%.

Seeking Alpha • Aug 14, 2026

Eton Pharmaceuticals Q2 Earnings Call Highlights

Eton Pharmaceuticals NASDAQ: ETON reported second-quarter revenue nearly doubled from a year earlier, driven by the relaunch of HEMANGEOL and growth across its pediatric endocrinology and rare-disease portfolio. The company raised its full-year revenue and profitability outlook while outlining plans to advance newly acquired and internally developed products.

MarketBeat • Aug 14, 2026